» Articles » PMID: 9989717

Tumour Necrosis Factor Alpha and Interleukin 1beta in Relapse of Crohn's Disease

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 1999 Feb 16
PMID 9989717
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Concentrations of proinflammatory cytokines are increased in the intestinal mucosa of patients with active Crohn's disease. Experimental immunotherapeutic interventions with anticytokine agents in refractory Crohn's disease show that tumour necrosis factor alpha (TNF alpha) may be an important mediator of inflammation. We investigated the relation between production of TNF alpha and interleukin 1beta by mononuclear cells of the colonic lamina propria in patients with remitting Crohn's disease and the risk of relapse.

Methods: We followed up 137 patients with Crohn's disease in steroid-induced remission for 1 year. Secretion of proinflammatory cytokines (tumour necrosis factor alpha [TNF alpha] and interleukin 1beta) was assessed after short-term culture of human lamina propria mononuclear cells.

Findings: Increased secretion of TNF alpha and interleukin 1beta were predictive for acute relapses within the next year. Site and extent of disease, baseline demographics, and serum acute-phase proteins had little predictive value.

Interpretation: TNF alpha is important as a target molecule for immune interventions in Crohn's disease. The capacity to produce TNF alpha or interleukin 1beta may identify patients who would benefit from anti-inflammatory remission maintenance.

Citing Articles

Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease.

Mishra N, Aden K, Blase J, Baran N, Bordoni D, Tran F Genome Med. 2022; 14(1):110.

PMID: 36153599 PMC: 9509553. DOI: 10.1186/s13073-022-01112-z.


Genotype-phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients.

Yoganathan P, Rossel J, Jordi S, Franc Y, Biedermann L, Misselwitz B BMC Gastroenterol. 2021; 21(1):310.

PMID: 34344313 PMC: 8336111. DOI: 10.1186/s12876-021-01880-9.


INTERACTIONS AMONG INTERLEUKIN-6, C-REACTIVE PROTEIN AND INTERLEUKIN-6 (-174) G/C POLYMORPHISM IN THE PATHOGENESIS OF CROHN'S DISEASE AND ULCERATIVE COLITIS.

Takac B, Mihaljevic S, Glavas-Obrovac L, Kibel A, Suver-Stevic M, Canecki-Varzic S Acta Clin Croat. 2020; 59(1):67-80.

PMID: 32724277 PMC: 7382872. DOI: 10.20471/acc.2020.59.01.09.


Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease.

Gareb B, Otten A, Frijlink H, Dijkstra G, Kosterink J Pharmaceutics. 2020; 12(6).

PMID: 32545207 PMC: 7356880. DOI: 10.3390/pharmaceutics12060539.


Effect of Loureirin B on Crohn's disease rat model induced by TNBS via IL-6/STAT3/NF-κB signaling pathway.

Sun X, Wen K, Xu Z, He Z, Wu B, Yang X Chin Med. 2020; 15:2.

PMID: 31911815 PMC: 6945620. DOI: 10.1186/s13020-019-0282-5.